Welcome to our dedicated page for Corvus Pharmaceu news (Ticker: CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceu stock.
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a clinical-stage biopharmaceutical company based in South San Francisco, California that focuses on immunotherapy for cancer and immune diseases. Company news frequently highlights progress with its lead ITK inhibitor, soquelitinib, and other clinical-stage candidates in oncology and immunology.
Investors following CRVS news can expect updates on clinical trial milestones, including the registration Phase 3 trial of soquelitinib in relapsed/refractory peripheral T cell lymphoma (PTCL) and randomized trials in atopic dermatitis. Corvus regularly reports interim and final data from Phase 1 and Phase 1b/2 studies, such as results in T cell lymphomas and atopic dermatitis, as well as presentations at major medical meetings like the American Society of Hematology (ASH), the European Society for Medical Oncology (ESMO) and rheumatology congresses.
News releases also cover business updates and financial results, where the company discusses its development strategy for ITK inhibition across cancer and immune diseases, cash runway, and collaborations. Additional announcements may describe progress with ciforadenant in metastatic renal cell cancer, the partner-led mupadolimab program in non-small cell lung cancer, and the Autoimmune Lymphoproliferative Syndrome (ALPS) trial conducted with the National Institute of Allergy and Infectious Diseases.
This CRVS news page aggregates these disclosures so readers can review clinical data announcements, regulatory designations, collaboration updates and corporate events in one place. For those tracking immuno-oncology and immune disease pipelines, Corvus news provides insight into the evolution of its ITK platform and related investigational therapies.
Corvus Pharmaceuticals (Nasdaq: CRVS) priced an upsized underwritten public offering of 7,900,677 shares at $22.15 per share, expected to generate approximately $175.0 million in gross proceeds before fees. The company granted underwriters a 30-day option to purchase up to an additional 1,185,101 shares at the public offering price less discounts.
Corvus said it expects to use net proceeds for working capital and general corporate purposes, including funding its Phase 3 T‑cell lymphoma trial and Phase 2 trials in atopic dermatitis, hidradenitis suppurativa and asthma. The offering is expected to close on or about January 23, 2026.
Corvus Pharmaceuticals (Nasdaq: CRVS) commenced an underwritten public offering of $150,000,000 of common stock and pre-funded warrants on January 20, 2026, with a 30-day underwriter option to purchase up to an additional $22,500,000 of common stock. Net proceeds are expected to be used for working capital and general corporate purposes, including capital expenditures and research and development for its Phase 3 T cell lymphoma program and Phase 2 trials in atopic dermatitis, hidradenitis suppurativa and asthma. Jefferies and Goldman Sachs are lead managers. The offering is subject to market conditions and will be made by prospectus supplement under an S-3 shelf declared effective August 15, 2024.
Corvus Pharmaceuticals (NASDAQ: CRVS) reported positive Phase 1 cohort 4 results for oral soquelitinib in moderate-to-severe atopic dermatitis. At Day 56 (n=12 soquelitinib, n=10 evaluable placebo) soquelitinib achieved EASI 75 in 75%, EASI 90 in 25% and IGA 0/1 in 33%, with mean EASI reduction of 72% vs 40% placebo and a statistically significant separation (p=0.035). Safety showed adverse events in 41.7% of treated patients vs 50% placebo; all events were Grade 1-2 with no serious adverse events. Biomarkers showed reductions in IL-4, IL-5, IL-17 and increased Treg cells. Corvus plans a ~200-patient Phase 2 trial in Q1 2026 with multiple dose arms and 12-week treatment.
Corvus Pharmaceuticals (NASDAQ: CRVS) will report results from cohort 4 of its randomized, blinded, placebo-controlled Phase 1 trial of soquelitinib in moderate to severe atopic dermatitis on Tuesday, January 20, 2026 at 8:00 am ET (5:00 am PT).
The company will host a conference call and live webcast with presentation slides; domestic dial-in is 1-800-717-1738 and international is 1-646-307-1865. The live webcast and slides are available via Corvus investor relations, and a replay will be available on the website for 60 days.
Corvus Pharmaceuticals (NASDAQ: CRVS) confirmed it will announce results from cohort 4 of its randomized, blinded, placebo-controlled Phase 1 trial of soquelitinib in moderate to severe atopic dermatitis in the second half of January 2026.
The company said the timing prompted cancellation of all previously planned conference attendance, including its presentation at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026.
Corvus Pharmaceuticals (NASDAQ: CRVS) presented final Phase 1/1b data for soquelitinib in T cell lymphoma at ASH on Dec 8, 2025. Key clinical results in the 200 mg twice-daily cohort (N=36) included median PFS 6.2 months and median OS 28.1 months, with 6 complete responses and an 18-month PFS of 30% and 24-month OS of 67% in a defined responder subgroup (N=24).
No dose-limiting toxicities or significant adverse events were observed up to 600 mg BID. Biomarker data show ITK inhibition with Th1 skewing and reductions in Th2/Th17 markers. The company is running a randomized Phase 3 (target n=150) in relapsed/refractory PTCL with interim data expected late 2026 and completion in 2027; soquelitinib has Orphan Drug and Fast Track designations.
Corvus Pharmaceuticals (NASDAQ: CRVS) provided a business update and reported Q3 2025 results on Nov 4, 2025. Key clinical milestones include completed enrollment in the soquelitinib atopic dermatitis Phase 1 extension cohort 4 with data anticipated in Jan 2026, a Phase 2 atopic dermatitis trial on track to start in early Q1 2026 (≈200 patients), and an ongoing registrational Phase 3 in relapsed/refractory PTCL (target ≈150 patients) with final Phase 1/1b data to be presented orally at ASH Dec 2025.
Financials: cash, cash equivalents and marketable securities of $65.7M as of Sept 30, 2025, expected to fund operations into Q4 2026. R&D expense for Q3 2025 was $8.5M vs $5.2M year-ago; net loss was $10.2M for the quarter.
Corvus Pharmaceuticals (NASDAQ: CRVS) will present final data from its Phase 1/1b trial of soquelitinib in relapsed/refractory T cell lymphomas at the 67th American Society of Hematology Annual Meeting & Exposition.
The oral presentation is scheduled for December 8, 2025, Session 625 (T Cell, NK Cell, or NK/T Cell Lymphomas), with a presentation slot from 11:15 AM–11:30 AM (session 10:30 AM–12:00 PM). Publication number is 778; the title reports final Phase 1 results for soquelitinib (SQL), an ITK inhibitor for R/R T cell lymphomas.
Corvus Pharmaceuticals (NASDAQ: CRVS) announced that its leadership team will hold one-on-one investor meetings and deliver a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston.
The fireside chat is scheduled for Monday, November 10, 2025 at 8:30 AM ET. A live webcast will be available and archived for 90 days via the company’s investor relations website.
Corvus Pharmaceuticals (NASDAQ: CRVS) will provide a business update and report third quarter 2025 financial results on November 4, 2025. The company will host a conference call and live webcast at 4:30 pm ET / 1:30 pm PT. Participants can dial 1-800-717-1738 (toll-free U.S.) or 1-646-307-1865 (international), or join via the instant telephone access link and the company’s investor relations webcast page. A replay of the webcast will be available on the Corvus website for 90 days.
FAQ
What is the current stock price of Corvus Pharmaceu (CRVS)?
What is the market cap of Corvus Pharmaceu (CRVS)?
